HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Rheumatology · Still's Disease Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Rheumatology · Still's Disease Competitive Landscape

7 findings · 14 signals · 1 insights

Type

Competitive Landscape Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 80%

Evidence

21 items

Sources

3

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Rheumatology · Still's Disease synthesizes 7 Competitiva findings across 14 active signals. 0 high-pressure competitive threats identified. 3 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Roche — baricitinib

    Roche is a direct competitive threat because it has a priority review program in Rheumatology · Systemic Juvenile Idiopathic Arthritis (baricitinib) and could narrow Lilly's development lead.

    View detail
  2. competitive

    Roche — baricitinib

    Roche is a direct competitive threat because it has a priority review program in Rheumatology · Systemic Juvenile Idiopathic Arthritis (baricitinib) and could narrow Lilly's development lead.

    View detail
  3. competitive

    Roche — PIT565

    Roche is a direct competitive threat because it is already approved in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    View detail
  4. competitive

    Roche — PIT565

    Roche is a direct competitive threat because it is already approved in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    View detail
  5. competitive

    Pfizer — PIT565

    Pfizer is a direct competitive threat because it has a development-stage program in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    View detail
  6. competitive

    Roche — PIT565

    Roche is a direct competitive threat because it is already approved in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    View detail
  7. competitive

    Pfizer — PIT565

    Pfizer is a direct competitive threat because it has a development-stage program in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 0 high-pressure competitive programs for portfolio displacement risk. Cross-reference 1 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Roche — baricitinib

    77%

    Roche is a direct competitive threat because it has a priority review program in Rheumatology · Systemic Juvenile Idiopathic Arthritis (baricitinib) and could narrow Lilly's development lead.

    Source: Roche

    View evidence

  • Roche — baricitinib

    77%

    Roche is a direct competitive threat because it has a priority review program in Rheumatology · Systemic Juvenile Idiopathic Arthritis (baricitinib) and could narrow Lilly's development lead.

    Source: Roche

    View evidence

  • Roche — PIT565

    75%

    Roche is a direct competitive threat because it is already approved in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    Source: Roche

    View evidence

  • Roche — PIT565

    75%

    Roche is a direct competitive threat because it is already approved in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    Source: Roche

    View evidence

  • Pfizer — PIT565

    80%

    Pfizer is a direct competitive threat because it has a development-stage program in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    Source: Pfizer

    View evidence

  • Roche — PIT565

    80%

    Roche is a direct competitive threat because it is already approved in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    Source: Humanexa Signals

    View evidence

  • Pfizer — PIT565

    95%

    Pfizer is a direct competitive threat because it has a development-stage program in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.

    Source: Pfizer

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Eli Lilly's Baricitinib Evaluated for Safety in Pediatric sJIA Patients

    Trial Update

  • Eli Lilly's Eloralintide Shows Promise for Osteoarthritis Knee Pain in Obese Patients

    Trial Update

  • Study on Pain Mechanisms in Juvenile Arthritis Launched by Washington University

    Trial Update

  • Study on Lung Disease Prevalence in Early Rheumatoid Arthritis Patients

    Trial Update

  • Phase II Study of D-0120 and Allopurinol in Gout by InventisBio

    Trial Update

  • Novartis initiates Phase II trial of MAS825 for Still's Disease

    Trial Update

  • Pilot rTMS Trial for Knee Arthritis Pain and Depression Shows Promise

    Trial Update

  • Novartis initiates ascending dose study of PIT565 for rheumatoid arthritis

    Trial Update

Insights

  • Emerging Competitive Dynamics in Rheumatology: Focus on Psoriatic Arthritis and RA Treatments

    Rheumatology · Psoriatic Arthritis

Companies

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Takeda

    4 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.